Although we've focused our remarks around business stability, we trust that you'll review all nine recommendations in our summer submission, which address, among other things, improved clinical trials, environment, regulatory modernization at Health Canada, and more accurate reporting of R and D by our industry in Canada by the Patented Medicine Prices Review Board.
Thank you for your attention today. Merci.